SCHEMBL812701

SCHEMBL812701

O=S(=O)(NC12CC3CC(CC(C3)C1)C2)c1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.71
ALDH1A1 P00352 2/20 0.71
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
KMT2A Q03164 2/20 0.51
EPHX2 P34913 3/20 0.48
FAAH O00519 1/20 0.47
PNMT P11086 1/20 0.47
MAPK1 P28482 2/20 0.46
MAPT P10636 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
HTT P42858 1/20 0.44
HSD11B1 P28845 1/20 0.44
THRB P10828 1/20 0.44
GFER P55789 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3324196 0.90 LMNA (0.68) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL31143809 0.83 LMNA (0.71) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL31143638 0.83 LMNA (0.71) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4070908 0.83 LMNA (0.71) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL31143673 0.83 ALDH1A1 (0.71) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL19807188 0.83 LMNA (1.00) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL19808587 0.83 LMNA (0.51) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL9095106 0.81 LMNA (0.60) LMNAALDH1A1SMN1; SMN2KMT2APNMT
SCHEMBL4066303 0.81 ALDH1A1 (0.56) LMNAALDH1A1SMN1; SMN2EPHX2PNMT
SCHEMBL21310019 0.80 LMNA (0.68) LMNAALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230288610-A1 WAVELENGTH SELECTIVE ABSORPTION FILTER AND DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2023-09-14 US disclosed
US-10202388-B2 Fused-ring compounds, pharmaceutical composition and uses thereof Shanghai De Novo Pharmatech Co., Ltd. (CN) 2019-02-12 US disclosed
US-20180022752-A1 FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF Shanghai De Novo Pharmatech Co., Ltd. (CN) 2018-01-25 US disclosed
US-20180022752-A1 FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF Shanghai De Novo Pharmatech Co., Ltd. (CN) 2018-01-25 US disclosed
EP-3239131-A1 NEW COMPOUNDS WITH ACTIVITY THAT PROTECTS AGAINST THE ACTION OF TOXINS AND VIRUSES IN INTRACELLULAR ACTION MODE Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) 2017-11-01 EP disclosed
US-20170233386-A1 Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2017-08-17 US disclosed
US-20170233386-A1 Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2017-08-17 US disclosed
US-9726932-B2 Optical film, optical compensation film, polarizing plate and liquid crystal display FUJIFILM CORPORATION (JP) 2017-08-08 US disclosed
US-9726932-B2 Optical film, optical compensation film, polarizing plate and liquid crystal display FUJIFILM CORPORATION (JP) 2017-08-08 US disclosed
US-9563075-B2 Method for manufacturing liquid crystal display device provided with front plate, and liquid crystal display device provided with front plate Konica Minolta, Inc. (JP) 2017-02-07 US disclosed
US-20070252293-A1 METHOD FOR MANUFACTURING AN OPTICAL FILM HAVING A CONVEXOCONCAVE STRUCTURE, OPTICAL FILM, WIRE GRID POLARIZER AND RETARDATION FILM KONICA MINOLTA OPTO, INC. (JP) 2007-11-01 US disclosed
US-20070252293-A1 METHOD FOR MANUFACTURING AN OPTICAL FILM HAVING A CONVEXOCONCAVE STRUCTURE, OPTICAL FILM, WIRE GRID POLARIZER AND RETARDATION FILM KONICA MINOLTA OPTO, INC. (JP) 2007-11-01 US disclosed
US-20070195226-A1 Polarizing plate and liquid crystal display FUJIFILM CORPORATION (JP) 2007-08-23 US disclosed
US-20070195226-A1 Polarizing plate and liquid crystal display FUJIFILM CORPORATION (JP) 2007-08-23 US disclosed
US-20070092663-A1 Cellulose ester film, polarizing plate and display KONICA MINOLTA OPTO, INC. 2007-04-26 US disclosed
US-20070092663-A1 Cellulose ester film, polarizing plate and display KONICA MINOLTA OPTO, INC. 2007-04-26 US disclosed
US-20070076155-A1 Optical film, optical compensation film, polarizing plate and liquid crystal display FUJI PHOTO FILM CO., LTD. (JP) 2007-04-05 US disclosed
US-20070076155-A1 Optical film, optical compensation film, polarizing plate and liquid crystal display FUJI PHOTO FILM CO., LTD. (JP) 2007-04-05 US disclosed
US-20070059458-A1 Cellulose acylate film, optically compensatory film, polarizing plate and liquid crystal display FUJI PHOTO FILM CO., LTD. (JP) 2007-03-15 US disclosed
US-20070059458-A1 Cellulose acylate film, optically compensatory film, polarizing plate and liquid crystal display FUJI PHOTO FILM CO., LTD. (JP) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202388-B2 Fused-ring compounds, pharmaceutical composition and uses thereof IDO1, IDO2, TDO2 LMNA 4813/4885ALDH1A1 2128/4885NPC1 2820/4885
US-20180022752-A1 FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF IDO1, IDO2, TDO2 LMNA 4813/4885ALDH1A1 2128/4885NPC1 2820/4885
US-20170233386-A1 Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action HAVCR2, MAVS, ANTXR2 LMNA 705/4885ALDH1A1 4539/4885NPC1 692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.